Published in Drug Week, November 20th, 2009
An international research team led by Professor Cohen-Armon of Tel-Aviv University found that potent phenanthridine derived polyADP-ribose polymerase (PARP) inhibitors that were originally designed to protect cells from cell-death under stress conditions (e.g. stroke or inflammation), efficiently eradicate MCF-7 and MDA231 breast cancer cells...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.